Phaseline

Companies › Ascendis Pharma Growth Disorders

Ascendis Pharma Growth Disorders: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Other; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lonapegsomatropin
Growth hormone receptor agonist
GHRPhase 2AchondroplasiaNov 2027
Navepegritide
C-type natriuretic peptide (CNP) analog
NPR2Phase 2AchondroplasiaNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06433557NavepegritidePhase 2AchondroplasiaOtherNov 2027
NCT06433557LonapegsomatropinPhase 2AchondroplasiaOtherNov 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

NPR2 (1) GHR (1)

Companies with the same targets

BioMarin Pharmaceutical Novo Nordisk Changchun GeneScience Pharmaceutical Ascendis Pharma Endocrinology Division Ascendis Pharma

Companies built like this

Ascendis Pharma Endocrinology Division Eirion Therapeutics Airway Therapeutics Inotrem Tego Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.